Advertisement

ALX Oncology Holdings Inc. ALXO

Set alert

Price alert · ALXO

All alert types
1.40 USD +0.18 +14.75%

As of Nov 2, 3:16 PM ET

Bid
1.40 × 2
Ask
1.41 × 2
1.20 Day range 1.42
0.862 52-week range 2.66
YTD
+23.89%
1 year
-9.09%
Open
1.23
Prev close
1.22
Mkt cap
193.59M
Vol
1.19M
Avg vol
1.27M
EPS
-1.13
P/E
0.00
Div yield
0.00%
More statistics
Low
1.20
High
1.42
Forward P/E
-0.68
Beta
1.04
Short ratio
8.58
Inst. own
88.21%
Dividend
0.00
Ex-div date
Earnings
Aug 8, 2024
50-d avg
1.50
200-d avg
6.33
1y target
7.67

2Y chart

Chart tools
Interval

Events in this range
  • Nov 7, 2024Earnings: -0.58; estimate -0.78; surprise 25.64%
  • Nov 12, 2024Rating: Cantor Fitzgerald · — → Overweight
  • Dec 18, 2024Rating: HC Wainwright & Co. · Buy → Buy
  • Dec 18, 2024Rating: Cantor Fitzgerald · Overweight → Overweight
  • Dec 19, 2024Downgrade: Jefferies · Buy → Hold
Signals (68)
NameDateAgo
MACD: Buy SignalOct 19, 20262 weeks ago
RSI: OversoldOct 13, 20262 weeks ago
RSI: OversoldOct 1, 20261 month ago
RSI: OversoldSep 22, 20261 month ago
SMA: BearishSep 16, 20261 month ago
MACD: Sell SignalSep 8, 20261 month ago
SMA: BullishSep 2, 20262 months ago
MACD: Buy SignalSep 2, 20262 months ago
MACD: Sell SignalAug 24, 20262 months ago
MACD: Buy SignalAug 21, 20262 months ago
MACD: Sell SignalAug 20, 20262 months ago
MACD: Buy SignalAug 19, 20262 months ago
MACD: Sell SignalAug 11, 20262 months ago
MACD: Buy SignalAug 10, 20262 months ago
MACD: Sell SignalJul 15, 20263 months ago
RSI: OverboughtJul 7, 20263 months ago
RSI: OverboughtJun 29, 20264 months ago
SMA: BullishJun 23, 20264 months ago
MACD: Buy SignalJun 23, 20264 months ago
RSI: OversoldJun 16, 20264 months ago
RSI: OversoldJun 10, 20264 months ago
RSI: OversoldJun 5, 20265 months ago
SMA: BearishJun 4, 20265 months ago
SMA: BearishJun 1, 20265 months ago
MACD: Sell SignalMay 26, 20265 months ago
SMA: BullishMay 8, 20265 months ago
SMA: BearishMay 7, 20265 months ago
SMA: BullishMay 6, 20266 months ago
MACD: Buy SignalApr 30, 20266 months ago
SMA: BearishMar 30, 20267 months ago
MACD: Sell SignalFeb 25, 20268 months ago
RSI: OverboughtFeb 19, 20268 months ago
RSI: OverboughtFeb 4, 20269 months ago
SMA: BullishJan 21, 20269 months ago
SMA: BearishJan 14, 20269 months ago
SMA: BullishJan 12, 20269 months ago
MACD: Buy SignalJan 12, 20269 months ago
MACD: Sell SignalDec 24, 202510 months ago
SMA: BearishDec 23, 202510 months ago
SMA: BullishDec 22, 202510 months ago
MACD: Buy SignalDec 5, 202511 months ago
MACD: Sell SignalDec 1, 202511 months ago
SMA: BearishNov 19, 202511 months ago
MACD: Buy SignalNov 18, 202511 months ago
SMA: BullishNov 17, 202511 months ago
SMA: BearishNov 4, 202512 months ago
MACD: Sell SignalOct 10, 20251 year ago
MACD: Buy SignalSep 24, 20251 year ago
RSI: OverboughtSep 24, 20251 year ago
MACD: Sell SignalSep 8, 20251 year ago
RSI: OverboughtAug 21, 20251 year ago
RSI: OverboughtAug 18, 20251 year ago
RSI: OverboughtJul 28, 20251 year ago
SMA: BullishJul 17, 20251 year ago
SMA: BullishJul 9, 20251 year ago
MACD: Buy SignalJul 9, 20251 year ago
MACD: Sell SignalJun 18, 20251 year ago
SMA: BearishJun 17, 20251 year ago
SMA: BullishJun 2, 20251 year ago
MACD: Buy SignalApr 10, 20251 year ago
RSI: OversoldApr 3, 20251 year ago
MACD: Sell SignalMar 13, 20251 year ago
MACD: Buy SignalFeb 20, 20251 year ago
SMA: BearishJan 24, 20251 year ago
MACD: Sell SignalJan 13, 20251 year ago
MACD: Buy SignalJan 7, 20251 year ago
MACD: Sell SignalDec 27, 20241 year ago
MACD: Buy SignalDec 23, 20241 year ago

Key statistics

Market cap
96.52M
Enterprise value
-45.77M
Trailing P/E
0.00
Forward P/E
-0.68
PEG ratio
0.00
Price / sales
0.00
Price / book
0.71
EPS (TTM)
-2.97
Beta
1.04
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
0
Revenue growth
0.00%
Free cash flow
-74.55M
Total cash
148.57M
Total debt
17.36M
Return on equity
-98.94%
Shares outstanding
52.74M
Short % of float
23.56%
50-day average
1.50
200-day average
6.33

Analyst view

Consensus: buy

Buy
Price target (mean) 7.67 +447.6% upside
Target (low)
2.00
Target (mean)
7.67
Target (high)
25.00
Ratings (0m) 7 4 buy · 3 hold · 0 sell
  • Strong buy2
  • Buy2
  • Hold3
  • Sell0
  • Strong sell0

Next earnings

Aug 8, 2024

Expected Aug 8, 2024. Consensus EPS estimate -0.38766.

Earnings history

Financials — quick view

All financials
ALXO Revenue — quarterly 0
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ALXO Net income — quarterly -17.97M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ALXO EPS — quarterly -0.13
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

ALXO recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 7, 2024Sep 1, 2024-0.78-0.58+0.20+25.64%
Aug 8, 2024Jun 1, 2024-0.77-0.76+0.01+1.30%
Aug 8, 2024Jun 1, 2024-0.77———
May 9, 2024Mar 1, 2024-0.87-0.71+0.16+18.39%
May 9, 2024Mar 1, 2024-0.87———
Mar 7, 2024Dec 1, 2023-0.84———

Upgrades / downgrades

ALXO analyst upgrades and downgrades
DateFirmActionFromTo
Dec 19, 2024JefferiesdownBuyHold
Dec 18, 2024Cantor FitzgeraldreitOverweightOverweight
Dec 18, 2024HC Wainwright & Co.reitBuyBuy
Nov 12, 2024Cantor Fitzgeraldreit—Overweight
Aug 16, 2024UBSmainBuyBuy
Aug 13, 2024HC Wainwright & Co.reitBuyBuy

About ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on ALXO — it syncs with the Stock Master app.

Insider holders

ALXO insider holders
InsiderRelationLatest transactionDateShares held
GARCIA PETER SChief Financial OfficerPurchaseJun 12, 2024122,348
HEMRAJANI REKHADirectorPurchaseDec 1, 202433,000
LETTMANN JASONChief Executive OfficerPurchaseMar 13, 2024171,620
PINTO SHELLYOfficerSaleAug 13, 202491,549
PONS JAUMEPresidentSaleAug 13, 2024591,510
RANDOLPH SOPHIAOfficerSaleAug 13, 2024325,711

Institution ownership

ALXO institution ownership
Holder% heldSharesValueReported
venBio Partners LLC18.39%9,699,92517.75MSep 29, 2024
FMR, LLC11.12%5,865,10610.73MSep 29, 2024
Tang Capital Management, LLC7.97%4,204,7357.69MSep 29, 2024
Vivo Capital, LLC7.65%4,034,5227.38MSep 29, 2024
Redmile Group, LLC7.27%3,836,5767.02MSep 29, 2024
Blackrock Inc.4.93%2,601,7764.76MSep 29, 2024

Fund ownership

ALXO fund ownership
Holder% heldSharesValueReported
Fidelity Small Cap Growth Fund3.20%1,689,6203.09MAug 30, 2024
Fidelity Series Small Cap Opportunities Fund2.00%1,057,2201.93MAug 30, 2024
Vanguard Total Stock Market Index Fund1.87%984,5861.80MSep 29, 2024
iShares Russell 2000 ETF1.64%867,1991.59MOct 30, 2024
Fidelity Select Portfolios - Biotechnology1.58%835,5041.53MOct 30, 2024
Fidelity Small Cap Growth K6 Fund1.18%621,4971.14MAug 30, 2024
Advertisement